Log in

Strongbridge Biopharma Stock Price, Forecast & Analysis (NASDAQ:SBBP)

$1.56
-0.01 (-0.64 %)
(As of 11/15/2019 01:06 AM ET)
Today's Range
$1.55
Now: $1.56
$1.63
50-Day Range
$1.58
MA: $2.08
$2.61
52-Week Range
$1.45
Now: $1.56
$5.69
Volume174,400 shs
Average Volume224,133 shs
Market Capitalization$84.56 million
P/E Ratio5.03
Dividend YieldN/A
Beta0.78
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SBBP
CUSIPN/A
Phone610-254-9200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.03 million
Cash Flow$0.76 per share
Book Value$1.47 per share

Profitability

Net Income$31.85 million

Miscellaneous

Employees106
Market Cap$84.56 million
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive SBBP News and Ratings via Email

Sign-up to receive the latest news and ratings for SBBP and its competitors with MarketBeat's FREE daily newsletter.


Strongbridge Biopharma (NASDAQ:SBBP) Frequently Asked Questions

What is Strongbridge Biopharma's stock symbol?

Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."

How were Strongbridge Biopharma's earnings last quarter?

Strongbridge Biopharma plc (NASDAQ:SBBP) released its earnings results on Thursday, November, 7th. The biotechnology company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.07. The biotechnology company earned $5.68 million during the quarter, compared to analysts' expectations of $5.06 million. Strongbridge Biopharma had a net margin of 211.37% and a return on equity of 45.77%. View Strongbridge Biopharma's Earnings History.

When is Strongbridge Biopharma's next earnings date?

Strongbridge Biopharma is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Strongbridge Biopharma.

What price target have analysts set for SBBP?

6 brokers have issued 12 month target prices for Strongbridge Biopharma's shares. Their forecasts range from $8.00 to $18.00. On average, they anticipate Strongbridge Biopharma's share price to reach $12.80 in the next year. This suggests a possible upside of 720.5% from the stock's current price. View Analyst Price Targets for Strongbridge Biopharma.

What is the consensus analysts' recommendation for Strongbridge Biopharma?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Strongbridge Biopharma in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Strongbridge Biopharma.

Has Strongbridge Biopharma been receiving favorable news coverage?

Media coverage about SBBP stock has been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Strongbridge Biopharma earned a news sentiment score of -1.4 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Strongbridge Biopharma.

Are investors shorting Strongbridge Biopharma?

Strongbridge Biopharma saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 701,500 shares, an increase of 5.6% from the August 30th total of 664,200 shares. Based on an average trading volume of 164,300 shares, the short-interest ratio is presently 4.3 days. Currently, 2.1% of the company's stock are short sold. View Strongbridge Biopharma's Current Options Chain.

Who are some of Strongbridge Biopharma's key competitors?

What other stocks do shareholders of Strongbridge Biopharma own?

Who are Strongbridge Biopharma's key executives?

Strongbridge Biopharma's management team includes the folowing people:
  • Mr. Matthew Pauls, CEO, Pres & Director (Age 48)
  • Mr. A. Brian Davis, Chief Financial Officer (Age 52)
  • Dr. Fredric Cohen, Chief Medical Officer (Age 54)
  • Dr. Per Marin M.D., Ph.D., Founder and Sr. Clinical Advisor
  • Mr. Peter J. Valentinsson, Sr. VP of Global Technical Operations

Who are Strongbridge Biopharma's major shareholders?

Strongbridge Biopharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include Essex Investment Management Co. LLC (0.77%). View Institutional Ownership Trends for Strongbridge Biopharma.

Which major investors are selling Strongbridge Biopharma stock?

SBBP stock was sold by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC. View Insider Buying and Selling for Strongbridge Biopharma.

How do I buy shares of Strongbridge Biopharma?

Shares of SBBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Strongbridge Biopharma's stock price today?

One share of SBBP stock can currently be purchased for approximately $1.56.

How big of a company is Strongbridge Biopharma?

Strongbridge Biopharma has a market capitalization of $84.56 million and generates $18.03 million in revenue each year. The biotechnology company earns $31.85 million in net income (profit) each year or $0.31 on an earnings per share basis. Strongbridge Biopharma employs 106 workers across the globe.View Additional Information About Strongbridge Biopharma.

What is Strongbridge Biopharma's official website?

The official website for Strongbridge Biopharma is http://www.strongbridgebio.com/.

How can I contact Strongbridge Biopharma?

Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at 610-254-9200 or via email at [email protected]


MarketBeat Community Rating for Strongbridge Biopharma (NASDAQ SBBP)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  263 (Vote Outperform)
Underperform Votes:  282 (Vote Underperform)
Total Votes:  545
MarketBeat's community ratings are surveys of what our community members think about Strongbridge Biopharma and other stocks. Vote "Outperform" if you believe SBBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SBBP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2019 by MarketBeat.com Staff

Featured Article: What does EPS mean?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel